Aristotle Chatziioannou

Aristotle Chatziioannou

Member HBio

Aristotle Chatziioannou (e-NIOS) is the Chief Executive Officer (CEO) of the e-NIOS Applications PC. He also holds the position of the Principal Investigator (Research Associate Professor) of the Metabolic Engineering and Bioinformatics Group, in the Institute of Biology, Medicinal Chemistry and Biotechnology of NHRF. He has a Ph.D. degree in Metabolic Engineering and Biomedical Informatics from the National Technical University of Athens (NTUA) Greece. He has co-authored more than 150 journal or conference papers, >835 citations, h-index: 14. Expertise: High-throughput and Big Data analysis, Data mining, Computational workflows, Translational bioinformatics, Integrated pathway analysis, Biomarker signature development, Distributed Computing.

e-NIOS is an SME working in the analysis of high throughput molecular data. It was founded in 2013 (Athens, Greece) by a research team with expertise in Molecular Biology, Engineering and Information Technology. e-NIOS is a spin-off company of the National Hellenic Research Foundation (NHRF) closely collaborating with the Institute of Biology, Medicinal Chemistry & Biotechnology (IBMCB) of NHRF (National Hellenic Research Foundation), the INSERM (Institut National de la Santé Et de la Recherche Médicale) and the DKFZ (Deutsches Krebs Forschungs Zentrum). e-NIOS assists research teams and industry partners with computational tools/workflows that analyse, complex designs of high-throughput molecular data and deliver their final biological interpretation. The company has currently seven employees, four of which hold a PhD. Recently, e-NIOS has become recipient of two EU-funded projects, namely:

  • the “INSPIRED” consortium (Marie-Curie action H2020-MSCA-RISE-2016) where e-NIOS (Greece), Univ. of Galway (Ireland), INSERM (France), metaSysX GmbH (Germany) and Mannkind Corp. (USA) will collaborate with the objective to develop novel approaches related to cell-stress response for the treatment of cancer, and
  • the “INNOCENT” consortium (Greece, Norway, Spain, Latvia, Slovakia), a EuroNanoMed II ERA-NET grant, aiming at the development of innovative multifunctional nanopharmaceuticals for breast cancer treatment, with emphasis on cancer stem cells.

For a detailed CV of Dr A.Chatziioannou